Fundsmith LLP’s Edwards Lifesciences EW Stock Holding History

Fundsmith LLP’s Portfolio EW Stock Details EW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-9,979	Closed	-$826K	–	41
2023 Q1	$826K	Hold	9,979	–	–	﹤0.01%	40
2022 Q4	$745K	Hold	9,979	–	–	﹤0.01%	38
2022 Q3	$825K	Buy	+9,979	New	+$960K	﹤0.01%	46

Other funds holding EW

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Fundsmith LLP's EW Position: Q2 2023 in Review

Fundsmith LLP sold out of Edwards Lifesciences (EW) in Q2 2023, closing a stake of 9,979 shares — an estimated $826K sold.

Fundsmith LLP first reported a position in EW in Q3 2022 and held it in 3 quarters. The position peaked at $826K in Q1 2023. 1,278 funds tracked by Wall St. Rank hold EW as of Q2 2023.

Fundsmith LLP reported no remaining Edwards Lifesciences position as of Q2 2023 after selling out during the quarter.
Fundsmith LLP sold 9,979 Edwards Lifesciences shares in Q2 2023, an estimated $826K.
Fundsmith LLP first reported a position in Edwards Lifesciences in Q3 2022 and held it in 3 quarters.
Fundsmith LLP's Edwards Lifesciences position peaked at $826K in Q1 2023.
1,278 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2023.

Based on Fundsmith LLP's 13F filing for Q2 2023, filed 14 Aug 2023.